aluates Reports

$ 0.0

Global Pet Recombinant Vaccine Market Research Report 2025

Published Date: February 2025

Report Code: QYRE-Auto-2N11762

Global Pet Recombinant Vaccine Market Research Report 2022

BUY CHAPTERS

Global Pet Recombinant Vaccine Market Research Report 2025

Code: QYRE-Auto-2N11762

Report

February 2025

Pages:80

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Vetoquinol

Ceva

Eli Lilly

Merial (Sanofi)

Pet Recombinant Vaccine Market Size

The global market for Pet Recombinant Vaccine was valued at US$ 539 million in the year 2024 and is projected to reach a revised size of US$ 785 million by 2031, growing at a CAGR of 5.6% during the forecast period.

Pet Recombinant Vaccine Market

Vaccines prepared at the genetic level for pet vaccination are called pet recombinant vaccines.

Pet medical care is the second largest segment in pet industry. In the UK, annual spending on veterinary and other pet services has risen from £2.6bn in 2015 to £4bn in 2021, a 54% increase in just six years. According to Vetnosis, the value of the global animal health industry will increase by 12% to $38.3 billion in 2021. White Paper on China"s Pet Healthy Consumption of JD shows that in 2023, there are 13.09 million pets entering middle age and old age. And pet aging is expected to be seen in the next few years. Changes in the age structure of pets will further bring about the development of the pet medical industry. According to the data of the 2022 China Pet Medical Industry White Paper, from the perspective of market size, the scale of China"s pet medical market is about ¥67.5 billion, accounting for about 22.5% of the entire pet industry. From the perspective of hospital operation time, pet hospitals within 5 years accounted for about 73%. About 11% of the pet hospitals have been in operation for more than 10 years. From the perspective of hospital turnover, nearly 40% of the hospitals have increased their annual turnover year-on-year, and the growth rate is mainly within 378%.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Pet Recombinant Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pet Recombinant Vaccine.

The Pet Recombinant Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pet Recombinant Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Pet Recombinant Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Pet Recombinant Vaccine Market Report

Report Metric	Details
Report Name	Pet Recombinant Vaccine Market
Accounted market size in year	US$ 539 million
Forecasted market size in 2031	US$ 785 million
CAGR	5.6%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Genetically Engineered Vaccines Genetically Recombinant Vaccines Transgenic Plant Vaccines DNA Vaccines
Segment by Application	Dog Cat Dird Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Bayer Healthcare, Vetoquinol S.A, Boehringer Ingelheim, Ceva, Eli Lilly, Heska, Merck Animal Health, Merial (Sanofi), Virbac, Pfizer
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pet Recombinant Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pet Recombinant Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Pet Recombinant Vaccine Market growing?

Ans: The Pet Recombinant Vaccine Market witnessing a CAGR of 5.6% during the forecast period 2025-2031.

What is the Pet Recombinant Vaccine Market size in 2031?

Ans: The Pet Recombinant Vaccine Market size in 2031 will be US$ 785 million.

What is the Pet Recombinant Vaccine Market share by region?

Ans: In the UK, annual spending on veterinary and other pet services has risen from £2.6bn in 2015 to £4bn in 2021, a 54% increase in just six years. According to the data of the 2022 China Pet Medical Industry White Paper, from the perspective of market size, the scale of China"s pet medical market is about ¥67.5 billion, accounting for about 22.5% of the entire pet industry.

Who are the main players in the Pet Recombinant Vaccine Market report?

Ans: The main players in the Pet Recombinant Vaccine Market are Bayer Healthcare, Vetoquinol S.A, Boehringer Ingelheim, Ceva, Eli Lilly, Heska, Merck Animal Health, Merial (Sanofi), Virbac, Pfizer

What are the Application segmentation covered in the Pet Recombinant Vaccine Market report?

Ans: The Applications covered in the Pet Recombinant Vaccine Market report are Dog, Cat, Dird, Others

What are the Type segmentation covered in the Pet Recombinant Vaccine Market report?

Ans: The Types covered in the Pet Recombinant Vaccine Market report are Genetically Engineered Vaccines, Genetically Recombinant Vaccines, Transgenic Plant Vaccines, DNA Vaccines

1 Pet Recombinant Vaccine Market Overview

1.1 Product Definition

1.2 Pet Recombinant Vaccine by Type

1.2.1 Global Pet Recombinant Vaccine Market Value Comparison by Type (2024 VS 2031)

1.2.2 Genetically Engineered Vaccines

1.2.3 Genetically Recombinant Vaccines

1.2.4 Transgenic Plant Vaccines

1.2.5 DNA Vaccines

1.3 Pet Recombinant Vaccine by Application

1.3.1 Global Pet Recombinant Vaccine Market Value by Application (2024 VS 2031)

1.3.2 Dog

1.3.3 Cat

1.3.4 Dird

1.3.5 Others

1.4 Global Pet Recombinant Vaccine Market Size Estimates and Forecasts

1.4.1 Global Pet Recombinant Vaccine Revenue 2020-2031

1.4.2 Global Pet Recombinant Vaccine Sales 2020-2031

1.4.3 Global Pet Recombinant Vaccine Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Pet Recombinant Vaccine Market Competition by Manufacturers

2.1 Global Pet Recombinant Vaccine Sales Market Share by Manufacturers (2020-2025)

2.2 Global Pet Recombinant Vaccine Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Pet Recombinant Vaccine Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Pet Recombinant Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Pet Recombinant Vaccine, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Pet Recombinant Vaccine, Product Type & Application

2.7 Global Key Manufacturers of Pet Recombinant Vaccine, Date of Enter into This Industry

2.8 Global Pet Recombinant Vaccine Market Competitive Situation and Trends

2.8.1 Global Pet Recombinant Vaccine Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Pet Recombinant Vaccine Players Market Share by Revenue

2.8.3 Global Pet Recombinant Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Pet Recombinant Vaccine Market Scenario by Region

3.1 Global Pet Recombinant Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Pet Recombinant Vaccine Sales by Region: 2020-2031

3.2.1 Global Pet Recombinant Vaccine Sales by Region: 2020-2025

3.2.2 Global Pet Recombinant Vaccine Sales by Region: 2026-2031

3.3 Global Pet Recombinant Vaccine Revenue by Region: 2020-2031

3.3.1 Global Pet Recombinant Vaccine Revenue by Region: 2020-2025

3.3.2 Global Pet Recombinant Vaccine Revenue by Region: 2026-2031

3.4 North America Pet Recombinant Vaccine Market Facts & Figures by Country

3.4.1 North America Pet Recombinant Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Pet Recombinant Vaccine Sales by Country (2020-2031)

3.4.3 North America Pet Recombinant Vaccine Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Pet Recombinant Vaccine Market Facts & Figures by Country

3.5.1 Europe Pet Recombinant Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Pet Recombinant Vaccine Sales by Country (2020-2031)

3.5.3 Europe Pet Recombinant Vaccine Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Pet Recombinant Vaccine Market Facts & Figures by Region

3.6.1 Asia Pacific Pet Recombinant Vaccine Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Pet Recombinant Vaccine Sales by Region (2020-2031)

3.6.3 Asia Pacific Pet Recombinant Vaccine Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Pet Recombinant Vaccine Market Facts & Figures by Country

3.7.1 Latin America Pet Recombinant Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Pet Recombinant Vaccine Sales by Country (2020-2031)

3.7.3 Latin America Pet Recombinant Vaccine Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Pet Recombinant Vaccine Market Facts & Figures by Country

3.8.1 Middle East and Africa Pet Recombinant Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Pet Recombinant Vaccine Sales by Country (2020-2031)

3.8.3 Middle East and Africa Pet Recombinant Vaccine Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Pet Recombinant Vaccine Sales by Type (2020-2031)

4.1.1 Global Pet Recombinant Vaccine Sales by Type (2020-2025)

4.1.2 Global Pet Recombinant Vaccine Sales by Type (2026-2031)

4.1.3 Global Pet Recombinant Vaccine Sales Market Share by Type (2020-2031)

4.2 Global Pet Recombinant Vaccine Revenue by Type (2020-2031)

4.2.1 Global Pet Recombinant Vaccine Revenue by Type (2020-2025)

4.2.2 Global Pet Recombinant Vaccine Revenue by Type (2026-2031)

4.2.3 Global Pet Recombinant Vaccine Revenue Market Share by Type (2020-2031)

4.3 Global Pet Recombinant Vaccine Price by Type (2020-2031)

5 Segment by Application

5.1 Global Pet Recombinant Vaccine Sales by Application (2020-2031)

5.1.1 Global Pet Recombinant Vaccine Sales by Application (2020-2025)

5.1.2 Global Pet Recombinant Vaccine Sales by Application (2026-2031)

5.1.3 Global Pet Recombinant Vaccine Sales Market Share by Application (2020-2031)

5.2 Global Pet Recombinant Vaccine Revenue by Application (2020-2031)

5.2.1 Global Pet Recombinant Vaccine Revenue by Application (2020-2025)

5.2.2 Global Pet Recombinant Vaccine Revenue by Application (2026-2031)

5.2.3 Global Pet Recombinant Vaccine Revenue Market Share by Application (2020-2031)

5.3 Global Pet Recombinant Vaccine Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Bayer Healthcare

6.1.1 Bayer Healthcare Company Information

6.1.2 Bayer Healthcare Description and Business Overview

6.1.3 Bayer Healthcare Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Bayer Healthcare Pet Recombinant Vaccine Product Portfolio

6.1.5 Bayer Healthcare Recent Developments/Updates

6.2 Vetoquinol S.A

6.2.1 Vetoquinol S.A Company Information

6.2.2 Vetoquinol S.A Description and Business Overview

6.2.3 Vetoquinol S.A Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Vetoquinol S.A Pet Recombinant Vaccine Product Portfolio

6.2.5 Vetoquinol S.A Recent Developments/Updates

6.3 Boehringer Ingelheim

6.3.1 Boehringer Ingelheim Company Information

6.3.2 Boehringer Ingelheim Description and Business Overview

6.3.3 Boehringer Ingelheim Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Boehringer Ingelheim Pet Recombinant Vaccine Product Portfolio

6.3.5 Boehringer Ingelheim Recent Developments/Updates

6.4 Ceva

6.4.1 Ceva Company Information

6.4.2 Ceva Description and Business Overview

6.4.3 Ceva Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Ceva Pet Recombinant Vaccine Product Portfolio

6.4.5 Ceva Recent Developments/Updates

6.5 Eli Lilly

6.5.1 Eli Lilly Company Information

6.5.2 Eli Lilly Description and Business Overview

6.5.3 Eli Lilly Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Eli Lilly Pet Recombinant Vaccine Product Portfolio

6.5.5 Eli Lilly Recent Developments/Updates

6.6 Heska

6.6.1 Heska Company Information

6.6.2 Heska Description and Business Overview

6.6.3 Heska Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Heska Pet Recombinant Vaccine Product Portfolio

6.6.5 Heska Recent Developments/Updates

6.7 Merck Animal Health

6.7.1 Merck Animal Health Company Information

6.7.2 Merck Animal Health Description and Business Overview

6.7.3 Merck Animal Health Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Merck Animal Health Pet Recombinant Vaccine Product Portfolio

6.7.5 Merck Animal Health Recent Developments/Updates

6.8 Merial (Sanofi)

6.8.1 Merial (Sanofi) Company Information

6.8.2 Merial (Sanofi) Description and Business Overview

6.8.3 Merial (Sanofi) Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Merial (Sanofi) Pet Recombinant Vaccine Product Portfolio

6.8.5 Merial (Sanofi) Recent Developments/Updates

6.9 Virbac

6.9.1 Virbac Company Information

6.9.2 Virbac Description and Business Overview

6.9.3 Virbac Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Virbac Pet Recombinant Vaccine Product Portfolio

6.9.5 Virbac Recent Developments/Updates

6.10 Pfizer

6.10.1 Pfizer Company Information

6.10.2 Pfizer Description and Business Overview

6.10.3 Pfizer Pet Recombinant Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Pfizer Pet Recombinant Vaccine Product Portfolio

6.10.5 Pfizer Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Pet Recombinant Vaccine Industry Chain Analysis

7.2 Pet Recombinant Vaccine Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Pet Recombinant Vaccine Production Mode & Process Analysis

7.4 Pet Recombinant Vaccine Sales and Marketing

7.4.1 Pet Recombinant Vaccine Sales Channels

7.4.2 Pet Recombinant Vaccine Distributors

7.5 Pet Recombinant Vaccine Customer Analysis

8 Pet Recombinant Vaccine Market Dynamics

8.1 Pet Recombinant Vaccine Industry Trends

8.2 Pet Recombinant Vaccine Market Drivers

8.3 Pet Recombinant Vaccine Market Challenges

8.4 Pet Recombinant Vaccine Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Vetoquinol

Ceva

Eli Lilly

Merial (Sanofi)

List of Tables

Table 1. Global Pet Recombinant Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Pet Recombinant Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Pet Recombinant Vaccine Market Competitive Situation by Manufacturers in 2024

Table 4. Global Pet Recombinant Vaccine Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Pet Recombinant Vaccine Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Pet Recombinant Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Pet Recombinant Vaccine Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Pet Recombinant Vaccine Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Pet Recombinant Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Pet Recombinant Vaccine, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Pet Recombinant Vaccine, Product Type & Application

Table 12. Global Key Manufacturers of Pet Recombinant Vaccine, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Pet Recombinant Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pet Recombinant Vaccine as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Pet Recombinant Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Pet Recombinant Vaccine Sales by Region (2020-2025) & (K Units)

Table 18. Global Pet Recombinant Vaccine Sales Market Share by Region (2020-2025)

Table 19. Global Pet Recombinant Vaccine Sales by Region (2026-2031) & (K Units)

Table 20. Global Pet Recombinant Vaccine Sales Market Share by Region (2026-2031)

Table 21. Global Pet Recombinant Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Pet Recombinant Vaccine Revenue Market Share by Region (2020-2025)

Table 23. Global Pet Recombinant Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Pet Recombinant Vaccine Revenue Market Share by Region (2026-2031)

Table 25. North America Pet Recombinant Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Pet Recombinant Vaccine Sales by Country (2020-2025) & (K Units)

Table 27. North America Pet Recombinant Vaccine Sales by Country (2026-2031) & (K Units)

Table 28. North America Pet Recombinant Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Pet Recombinant Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Pet Recombinant Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Pet Recombinant Vaccine Sales by Country (2020-2025) & (K Units)

Table 32. Europe Pet Recombinant Vaccine Sales by Country (2026-2031) & (K Units)

Table 33. Europe Pet Recombinant Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Pet Recombinant Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Pet Recombinant Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Pet Recombinant Vaccine Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Pet Recombinant Vaccine Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Pet Recombinant Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Pet Recombinant Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Pet Recombinant Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Pet Recombinant Vaccine Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Pet Recombinant Vaccine Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Pet Recombinant Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Pet Recombinant Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Pet Recombinant Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Pet Recombinant Vaccine Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Pet Recombinant Vaccine Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Pet Recombinant Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Pet Recombinant Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Pet Recombinant Vaccine Sales (K Units) by Type (2020-2025)

Table 51. Global Pet Recombinant Vaccine Sales (K Units) by Type (2026-2031)

Table 52. Global Pet Recombinant Vaccine Sales Market Share by Type (2020-2025)

Table 53. Global Pet Recombinant Vaccine Sales Market Share by Type (2026-2031)

Table 54. Global Pet Recombinant Vaccine Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Pet Recombinant Vaccine Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Pet Recombinant Vaccine Revenue Market Share by Type (2020-2025)

Table 57. Global Pet Recombinant Vaccine Revenue Market Share by Type (2026-2031)

Table 58. Global Pet Recombinant Vaccine Price (US$/Unit) by Type (2020-2025)

Table 59. Global Pet Recombinant Vaccine Price (US$/Unit) by Type (2026-2031)

Table 60. Global Pet Recombinant Vaccine Sales (K Units) by Application (2020-2025)

Table 61. Global Pet Recombinant Vaccine Sales (K Units) by Application (2026-2031)

Table 62. Global Pet Recombinant Vaccine Sales Market Share by Application (2020-2025)

Table 63. Global Pet Recombinant Vaccine Sales Market Share by Application (2026-2031)

Table 64. Global Pet Recombinant Vaccine Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Pet Recombinant Vaccine Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Pet Recombinant Vaccine Revenue Market Share by Application (2020-2025)

Table 67. Global Pet Recombinant Vaccine Revenue Market Share by Application (2026-2031)

Table 68. Global Pet Recombinant Vaccine Price (US$/Unit) by Application (2020-2025)

Table 69. Global Pet Recombinant Vaccine Price (US$/Unit) by Application (2026-2031)

Table 70. Bayer Healthcare Company Information

Table 71. Bayer Healthcare Description and Business Overview

Table 72. Bayer Healthcare Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Bayer Healthcare Pet Recombinant Vaccine Product

Table 74. Bayer Healthcare Recent Developments/Updates

Table 75. Vetoquinol S.A Company Information

Table 76. Vetoquinol S.A Description and Business Overview

Table 77. Vetoquinol S.A Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Vetoquinol S.A Pet Recombinant Vaccine Product

Table 79. Vetoquinol S.A Recent Developments/Updates

Table 80. Boehringer Ingelheim Company Information

Table 81. Boehringer Ingelheim Description and Business Overview

Table 82. Boehringer Ingelheim Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Boehringer Ingelheim Pet Recombinant Vaccine Product

Table 84. Boehringer Ingelheim Recent Developments/Updates

Table 85. Ceva Company Information

Table 86. Ceva Description and Business Overview

Table 87. Ceva Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Ceva Pet Recombinant Vaccine Product

Table 89. Ceva Recent Developments/Updates

Table 90. Eli Lilly Company Information

Table 91. Eli Lilly Description and Business Overview

Table 92. Eli Lilly Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Eli Lilly Pet Recombinant Vaccine Product

Table 94. Eli Lilly Recent Developments/Updates

Table 95. Heska Company Information

Table 96. Heska Description and Business Overview

Table 97. Heska Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Heska Pet Recombinant Vaccine Product

Table 99. Heska Recent Developments/Updates

Table 100. Merck Animal Health Company Information

Table 101. Merck Animal Health Description and Business Overview

Table 102. Merck Animal Health Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Merck Animal Health Pet Recombinant Vaccine Product

Table 104. Merck Animal Health Recent Developments/Updates

Table 105. Merial (Sanofi) Company Information

Table 106. Merial (Sanofi) Description and Business Overview

Table 107. Merial (Sanofi) Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. Merial (Sanofi) Pet Recombinant Vaccine Product

Table 109. Merial (Sanofi) Recent Developments/Updates

Table 110. Virbac Company Information

Table 111. Virbac Description and Business Overview

Table 112. Virbac Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. Virbac Pet Recombinant Vaccine Product

Table 114. Virbac Recent Developments/Updates

Table 115. Pfizer Company Information

Table 116. Pfizer Description and Business Overview

Table 117. Pfizer Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 118. Pfizer Pet Recombinant Vaccine Product

Table 119. Pfizer Recent Developments/Updates

Table 120. Key Raw Materials Lists

Table 121. Raw Materials Key Suppliers Lists

Table 122. Pet Recombinant Vaccine Distributors List

Table 123. Pet Recombinant Vaccine Customers List

Table 124. Pet Recombinant Vaccine Market Trends

Table 125. Pet Recombinant Vaccine Market Drivers

Table 126. Pet Recombinant Vaccine Market Challenges

Table 127. Pet Recombinant Vaccine Market Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

Table 131. Authors List of This Report

List of Figures

Figure 1. Product Picture of Pet Recombinant Vaccine

Figure 2. Global Pet Recombinant Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Pet Recombinant Vaccine Market Share by Type: 2024 & 2031

Figure 4. Genetically Engineered Vaccines Product Picture

Figure 5. Genetically Recombinant Vaccines Product Picture

Figure 6. Transgenic Plant Vaccines Product Picture

Figure 7. DNA Vaccines Product Picture

Figure 8. Global Pet Recombinant Vaccine Market Value by Application (2020-2031) & (US$ Million)

Figure 9. Global Pet Recombinant Vaccine Market Share by Application: 2024 & 2031

Figure 10. Dog

Figure 11. Cat

Figure 12. Dird

Figure 13. Others

Figure 14. Global Pet Recombinant Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Pet Recombinant Vaccine Market Size (2020-2031) & (US$ Million)

Figure 16. Global Pet Recombinant Vaccine Sales (2020-2031) & (K Units)

Figure 17. Global Pet Recombinant Vaccine Average Price (US$/Unit) & (2020-2031)

Figure 18. Pet Recombinant Vaccine Report Years Considered

Figure 19. Pet Recombinant Vaccine Sales Share by Manufacturers in 2024

Figure 20. Global Pet Recombinant Vaccine Revenue Share by Manufacturers in 2024

Figure 21. Global 5 and 10 Largest Pet Recombinant Vaccine Players: Market Share by Revenue in Pet Recombinant Vaccine in 2024

Figure 22. Pet Recombinant Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 23. Global Pet Recombinant Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 24. North America Pet Recombinant Vaccine Sales Market Share by Country (2020-2031)

Figure 25. North America Pet Recombinant Vaccine Revenue Market Share by Country (2020-2031)

Figure 26. United States Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. Canada Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. Europe Pet Recombinant Vaccine Sales Market Share by Country (2020-2031)

Figure 29. Europe Pet Recombinant Vaccine Revenue Market Share by Country (2020-2031)

Figure 30. Germany Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. France Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. U.K. Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Italy Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Russia Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Asia Pacific Pet Recombinant Vaccine Sales Market Share by Region (2020-2031)

Figure 36. Asia Pacific Pet Recombinant Vaccine Revenue Market Share by Region (2020-2031)

Figure 37. China Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Japan Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. South Korea Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. India Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Australia Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. China Taiwan Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Indonesia Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Thailand Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Malaysia Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Latin America Pet Recombinant Vaccine Sales Market Share by Country (2020-2031)

Figure 47. Latin America Pet Recombinant Vaccine Revenue Market Share by Country (2020-2031)

Figure 48. Mexico Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Brazil Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Argentina Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Middle East and Africa Pet Recombinant Vaccine Sales Market Share by Country (2020-2031)

Figure 52. Middle East and Africa Pet Recombinant Vaccine Revenue Market Share by Country (2020-2031)

Figure 53. Turkey Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Saudi Arabia Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. UAE Pet Recombinant Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 56. Global Sales Market Share of Pet Recombinant Vaccine by Type (2020-2031)

Figure 57. Global Revenue Market Share of Pet Recombinant Vaccine by Type (2020-2031)

Figure 58. Global Pet Recombinant Vaccine Price (US$/Unit) by Type (2020-2031)

Figure 59. Global Sales Market Share of Pet Recombinant Vaccine by Application (2020-2031)

Figure 60. Global Revenue Market Share of Pet Recombinant Vaccine by Application (2020-2031)

Figure 61. Global Pet Recombinant Vaccine Price (US$/Unit) by Application (2020-2031)

Figure 62. Pet Recombinant Vaccine Value Chain

Figure 63. Channels of Distribution (Direct Vs Distribution)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Sodium Picosulfate Oral Drug Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-14H19081

Mon Feb 17 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Intrathecal Drug Pump Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-7E13922

Mon Feb 17 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Algae Omega3 Ingredient Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22X3084

Mon Feb 17 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Animal Immunoglobulin Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-6Q19165

Mon Feb 17 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions